Drug shortages in the US – their causes, both direct and indirect, and challenges and approaches in how best to alleviate them – was naturally a recurring theme across the Association for Accessible Medicines’ Access! two-day annual conference, held earlier this month in Tampa, Florida.
‘You Step Up, You Bring Things Back To Market’: CDER’s Corrigan-Curay On Shortages
Corrigan-Curay Praises Industry While Reiterating Help For More Reliable Manufacturing
Principal deputy director of the US FDA’s Center for Drug Evaluation and Research, Jacqueline Corrigan-Curay, used part of her 20-minute keynote address at the recent AAM Access! annual conference to focus on drug shortages that persist across the US.
More from Manufacturing
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
• By
Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.
• By
Biocon Biologics is partnering with Civica to supply insulin aspart drug substance that will be used for final US manufacturing by Civica at its plant in Petersburg, Virginia.
• By
Viatris anticipates that half-a-billion dollars will disappear from its top line in 2025 on the back of the recent import alert for its oral solids facility in Indore, with much of the pain being caused by the firm’s failure to have its generic version of Revlimid exempt from the restrictions.